For 16 weeks, adolescents and adults with Down syndrome took a twice-daily medicine designed to turn down overactive immune signals—and researchers at the University of Colorado Anschutz saw signs of reduced inflammation and improvement in some skin conditions.

Down syndrome is caused by an extra copy of chromosome 21. That chromosome carries genes for several receptors that respond to interferons, signaling molecules that help regulate the immune system. Earlier research at the Linda Crnic Institute for Down Syndrome found that this genetic difference can drive persistently high interferon signaling and broader immune disruption. The new phase 2 trial tested whether a drug could reduce that excess activity and potentially help with health problems linked to it.

The drug, tofacitinib, is a JAK inhibitor: it blocks some of the signals involved in immune responses and inflammation. The trial enrolled people with Down syndrome who also had inflammatory skin conditions, including hidradenitis suppurativa, which can cause painful skin lesions, and alopecia areata, which can lead to hair loss. Participants took the medicine twice a day for 16 weeks, with an optional extension lasting up to 40 weeks. Researchers tracked safety, skin symptoms, blood-based biological markers and thinking and behavior through neuropsychological assessments.

The study met its planned safety goal. Researchers reported a safety profile similar to that seen in the general population, though they stressed that JAK inhibitors have known risks and that larger studies are needed to understand long-term safety for people with Down syndrome. Blood tests showed significant drops in interferon activity, inflammatory cytokine scores and inflammation-linked metabolites, including quinolinic acid, a compound known to have harmful effects on the brain. Analyses of genes, proteins and metabolites suggested the treatment changed specific inflammatory pathways rather than shutting down immune responses altogether.

Participants also showed improvements in their inflammatory skin conditions, especially hidradenitis suppurativa and alopecia areata. Researchers assessed these changes with standard clinical scores and measures of how skin problems affected quality of life. Joaquín Espinosa, the institute’s executive director and a professor of pharmacology, called the work an important step toward new treatments. First author Angela Rachubinski said several abnormal inflammatory markers moved closer to levels seen in people without Down syndrome, while normal immune defenses appeared to remain intact.

The team also observed better results on selected tests of attention, memory, vocabulary and behavior, along with favorable changes in some reports from participants and caregivers. Those findings are preliminary, not proof that tofacitinib improves brain health. Still, they give researchers a reason to study the possibility further, including potential links to Alzheimer's disease. The trial offers early evidence that treating immune overactivity may help with more than one condition at once; the next step is larger research to test how lasting and widespread those benefits may be.